{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:51:00Z","timestamp":1782305460143,"version":"3.54.5"},"reference-count":10,"publisher":"JLE","issue":"2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Dermatol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1684\/ejd.2019.3501","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:25:12Z","timestamp":1696865112000},"page":"217-218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Methotrexate is safe and effective as long-term treatment for bullous pemphigoid"],"prefix":"10.1684","volume":"29","author":[{"given":"Stephanie","family":"Delaumenie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safae","family":"Assikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Prudhomme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Matei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Souyri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Dalmay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Bedane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18929","published-online":{"date-parts":[[2019,5,27]]},"reference":[{"key":"3501_CR1","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/jid.2010.301","volume":"131","author":"S Bastuji-Garin","year":"2011","unstructured":"Bastuji-Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 2011;131: 637\u201343.","journal-title":"J Invest Dermatol"},{"key":"3501_CR2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000106574","volume":"215","author":"N Cordel","year":"2007","unstructured":"Cordel N, Chosidow O, Hellot M-F, et al. Neurological disorders in patients with bullous pemphigoid. Dermatol Basel Switz 2007;215:187\u201391.","journal-title":"Dermatol Basel Switz"},{"key":"3501_CR3","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1684\/ejd.2017.3066","volume":"27","author":"N Milani-Nejad","year":"2017","unstructured":"Milani-Nejad N, Zhang M, Kaffenberger J. The association between bullous pemphigoid and neurological disorders: a systematic review. Eur J Dermatol 2017;27:472\u201381.","journal-title":"Eur J Dermatol"},{"key":"3501_CR4","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/j.1365-2133.2011.10531.x","volume":"165","author":"A Du-Thanh","year":"2011","unstructured":"Du-Thanh A, Merlet S, Maillard H, et al. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. Br J Dermatol 2011;165:1337\u201343.","journal-title":"Br J Dermatol"},{"key":"3501_CR5","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/jid.2008.412","volume":"129","author":"P Joly","year":"2009","unstructured":"Joly P, Roujeau J-C, Benichou J, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bul-lous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009;129:1681\u20137.","journal-title":"J Invest Dermatol"},{"key":"3501_CR6","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/j.1365-2133.2009.09246.x","volume":"161","author":"HM G\u00fcrcan","year":"2009","unstructured":"G\u00fcrcan HM, Ahmed AR. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol 2009;161:723\u201331.","journal-title":"Br J Dermatol"},{"key":"3501_CR7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1684\/ejd.2017.3027","volume":"27","author":"R Binois","year":"2017","unstructured":"Binois R, Nadal M, Esteve E, et al. Cutaneous Kaposi sarcoma during treatment with superpotent topical steroids and methotrexate for bullous pemphigoid: three cases. Eur J Dermatol 2017;27:369\u201374.","journal-title":"Eur J Dermatol"},{"key":"3501_CR8","volume-title":"Acta Derm Venereol","author":"K Kridin","year":"2018","unstructured":"Kridin K, Bergman R. Mortality in patients with bullous pemphigoid: a retrospective cohort study, systematic review and meta-analysis. Acta Derm Venereol 2018. doi: 10.2340\/00015555-2930.(ahead of print)."},{"key":"3501_CR9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/j.1365-2133.1997.tb03654.x","volume":"136","author":"P Bernard","year":"1997","unstructured":"Bernard P, Bedane C, Bonnetblanc JM. Anti-BP180 autoantibodies as a marker of poor prognosis in bullous pemphigoid: a cohort analysis of 94 elderly patients. Br J Dermatol 1997;136:694\u20138.","journal-title":"Br J Dermatol"},{"key":"3501_CR10","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1684\/ejd.2016.2793","volume":"26","author":"F Bardazzi","year":"2016","unstructured":"Bardazzi F, Barisani A, Magnano M, et al. Autoantibody serum levels and intensity of pruritus in bullous pemphigoid. Eur J Dermatol 2016; 26:390\u20131.","journal-title":"Eur J Dermatol"}],"container-title":["European Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1684\/ejd.2019.3501.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1684\/ejd.2019.3501\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1684\/ejd.2019.3501.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.jle.com\/10.1684\/ejd.2019.3501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:22:57Z","timestamp":1741191777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jle.com\/10.1684\/ejd.2019.3501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["3501"],"URL":"https:\/\/doi.org\/10.1684\/ejd.2019.3501","relation":{},"ISSN":["1952-4013"],"issn-type":[{"value":"1952-4013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"27 Mai 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}